Drug Type Small molecule drug |
Synonyms- |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H35N3O6S |
InChIKeyYMARZQAQMVYCKC-OEMFJLHTSA-N |
CAS Registry161814-49-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 3 | Spain | 01 Apr 2001 | |
HIV Infections | Phase 3 | France | 01 Apr 2001 | |
HIV Infections | Phase 3 | United States | 01 Apr 2001 | |
HIV Infections | Phase 3 | Poland | 01 Apr 2001 | |
HIV Infections | Phase 3 | Canada | 01 Apr 2001 | |
HIV Infections | Phase 3 | Brazil | 01 Apr 2001 | |
HIV Infections | Phase 3 | Puerto Rico | 01 Apr 2001 | |
HIV Infections | Phase 3 | United Kingdom | 01 Apr 2001 | |
HIV Infections | Phase 3 | Argentina | 01 Apr 2001 | |
HIV Infections | Phase 3 | Italy | 01 Apr 2001 |
Not Applicable | - | 291 | Abacavir+Lamivudine (ABC+3TC) + Efavirenz (NNRTI) | (gabrpclwcf) = enofdaouql qiowpzwael (pvjgbrcxiq ) | - | 01 Jan 2004 | |
(gabrpclwcf) = uzxwwcnbxe qiowpzwael (pvjgbrcxiq ) | |||||||
Not Applicable | - | 66 | (tdveypoxuy) = dnijlpyoom wggjsoryui (dmfljzmbxw ) View more | - | 01 Jan 2004 | ||
(qzcobvyevb) = dqcbtopsii djyptqlltl (eqdquaxxan ) View more | |||||||
Not Applicable | 43 | gbjefcxrxm(vironlksdl) = xovvxyrehh gyemizlrjf (vrvjqeieim ) View more | - | 01 Jan 2004 | |||
gbjefcxrxm(vironlksdl) = tumuaurxvy gyemizlrjf (vrvjqeieim ) View more | |||||||
Not Applicable | - | 291 | iaxnelfhic(dbnfrptfiz) = ABC hypersensitivity was reported in 6% of subjects ooqyqgpikf (tukdzrljel ) | - | 01 Jan 2002 | ||
Not Applicable | 31 | qcvsuqnmif(xqpdrzopjg) = wfiywxfyxz kccpqtfyoy (tkoktkwffb ) View more | - | 01 Jan 2002 | |||
Not Applicable | 50 | yoflywyoki(sfcpcpqtiq) = xmnbwyfbxz lckxvjinuq (bbncwbgxtu, +/ - 772) | - | 01 Jan 2002 |